1. Chase, T. N., Engber, T. M., & Mouradian, M. M. (1994). Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson’s disease. Neurology, 44, S15–S18.
2. Ebadi, M., & Srinivasan, S. K. (1995). Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Pharmacological Reviews, 47, 575–604.
3. Muller, T., Hefter, H., Hueber, R., Jost, W. H., Leenders, K. L., Odin, P., et al. (2004). Is levodopa toxic? Journal of Neurology, 251(Suppl 6), VI/44–VI/46.
4. Naudin, B., Bonnet, J. J., & Costentin, J. (1995). Acute l-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice. Brain Research, 701, 151–157.
5. Olanow, C. W., Agid, Y., Mizuno, Y., Albanese, A., Bonuccelli, U., Damier, P., et al. (2004). Levodopa in the treatment of Parkinson’s disease: current controversies. Movement Disorders, 19, 997–1005.